ECIS Highlights Increase in Lung Cancer Among Women in Europe
Latest Cancer Mapping Shows Key Trends Across Europe
The updated European Cancer Information System (ECIS) has refreshed its epidemiological data, revealing critical cancer trends across Europe. A significant increase in lung cancer cases among women has been observed, while a decline is noted among men. Managed by the Joint Research Centre (JRC) and supported by data from over 125 cancer registries across 32 countries, ECIS provides valuable insights into cancer incidence and mortality.
Key Findings:
Lung Cancer: Cases among women are increasing, while incidence in men is declining.
Stomach Cancer: Both incidence and mortality rates are steadily decreasing.
Breast Cancer: It remains the most diagnosed cancer in women, but mortality rates are decreasing due to advancements in care.
ECIS plays a vital role in understanding these trends, enabling targeted policymaking, enhancing public awareness, and fostering research efforts. Supporting such initiatives is essential to improve cancer prevention and control across Europe.
👉For more information and to explore the data, visit the ECIS website:
#EuCanScreen #CancerScreening #HealthCare #CancerPrevention #LungCancer
🔗 Please don’t forget to Subscribe to EuCanScreen Newsletter! 💪
Subscribe to our newsletter to get news and updates.
Subscribe to our newsletter to get news and updates.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor HADEA can be held responsible for them.
The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.
This project has received funding from the European Union’s EU4HEALTH Programme under the Grant Agreement no 101162959